File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: The NK-cell tumor study group study

TitlePhase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: The NK-cell tumor study group study
Authors
Issue Date2011
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
Journal Of Clinical Oncology, 2011, v. 29 n. 33, p. 4410-4416 How to Cite?
AbstractPurpose: To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a phase II study of the steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) regimen. Patients and Methods: Patients with newly diagnosed stage IV, relapsed, or refractory disease and a performance status of 0 to 2 were eligible. Two cycles of SMILE chemotherapy were administered as the protocol treatment. The primary end point was the overall response rate (ORR) after the protocol treatment. Results: A total of 38 eligible patients were enrolled. The median age was 47 years (range, 16 to 67 years), and the male:female ratio was 21:17. The disease status was newly diagnosed stage IV in 20 patients, first relapse in 14 patients, and primary refractory in four patients. The eligibility was revised to include lymphocyte counts of 500/μL or more because the first two patients died from infections. No treatment-related deaths were observed after the revision. The ORR and complete response rate after two cycles of SMILE chemotherapy were 79% (90% CI, 65% to 89%) and 45%, respectively. In the 28 patients who completed the protocol treatment, 19 underwent hematopoietic stem-cell transplantation. The 1-year overall survival rate was 55% (95% CI, 38% to 69%). Grade 4 neutropenia was observed in 92% of the patients. The most common grade 3 or 4 nonhematologic complication was infection (61%). Conclusion: SMILE chemotherapy is an effective treatment for newly diagnosed stage IV, relapsed or refractory ENKL. Myelosuppression and infection during the treatment should be carefully managed. © 2011 by American Society of Clinical Oncology.
Persistent Identifierhttp://hdl.handle.net/10722/163418
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYamaguchi, Men_US
dc.contributor.authorKwong, YLen_US
dc.contributor.authorKim, WSen_US
dc.contributor.authorMaeda, Yen_US
dc.contributor.authorHashimoto, Cen_US
dc.contributor.authorSuh, Cen_US
dc.contributor.authorIzutsu, Ken_US
dc.contributor.authorIshida, Fen_US
dc.contributor.authorIsobe, Yen_US
dc.contributor.authorSueoka, Een_US
dc.contributor.authorSuzumiya, Jen_US
dc.contributor.authorKodama, Ten_US
dc.contributor.authorKimura, Hen_US
dc.contributor.authorHyo, Ren_US
dc.contributor.authorNakamura, Sen_US
dc.contributor.authorOshimi, Ken_US
dc.contributor.authorSuzuki, Ren_US
dc.date.accessioned2012-09-05T05:31:09Z-
dc.date.available2012-09-05T05:31:09Z-
dc.date.issued2011en_US
dc.identifier.citationJournal Of Clinical Oncology, 2011, v. 29 n. 33, p. 4410-4416en_US
dc.identifier.issn0732-183Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/163418-
dc.description.abstractPurpose: To explore a more effective treatment for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a phase II study of the steroid (dexamethasone), methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) regimen. Patients and Methods: Patients with newly diagnosed stage IV, relapsed, or refractory disease and a performance status of 0 to 2 were eligible. Two cycles of SMILE chemotherapy were administered as the protocol treatment. The primary end point was the overall response rate (ORR) after the protocol treatment. Results: A total of 38 eligible patients were enrolled. The median age was 47 years (range, 16 to 67 years), and the male:female ratio was 21:17. The disease status was newly diagnosed stage IV in 20 patients, first relapse in 14 patients, and primary refractory in four patients. The eligibility was revised to include lymphocyte counts of 500/μL or more because the first two patients died from infections. No treatment-related deaths were observed after the revision. The ORR and complete response rate after two cycles of SMILE chemotherapy were 79% (90% CI, 65% to 89%) and 45%, respectively. In the 28 patients who completed the protocol treatment, 19 underwent hematopoietic stem-cell transplantation. The 1-year overall survival rate was 55% (95% CI, 38% to 69%). Grade 4 neutropenia was observed in 92% of the patients. The most common grade 3 or 4 nonhematologic complication was infection (61%). Conclusion: SMILE chemotherapy is an effective treatment for newly diagnosed stage IV, relapsed or refractory ENKL. Myelosuppression and infection during the treatment should be carefully managed. © 2011 by American Society of Clinical Oncology.en_US
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/en_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Adverse Effects - Therapeutic Useen_US
dc.subject.meshAsparaginase - Administration & Dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLymphoma, Extranodal Nk-T-Cell - Drug Therapy - Mortality - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshNose Neoplasms - Drug Therapy - Pathologyen_US
dc.subject.meshRecurrenceen_US
dc.titlePhase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal Natural Killer (NK)/T-cell lymphoma, nasal type: The NK-cell tumor study group studyen_US
dc.typeArticleen_US
dc.identifier.emailKwong, YL:ylkwong@hku.hken_US
dc.identifier.authorityKwong, YL=rp00358en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1200/JCO.2011.35.6287en_US
dc.identifier.pmid21990393-
dc.identifier.scopuseid_2-s2.0-81755172136en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81755172136&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume29en_US
dc.identifier.issue33en_US
dc.identifier.spage4410en_US
dc.identifier.epage4416en_US
dc.identifier.isiWOS:000297257400018-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridYamaguchi, M=7404824526en_US
dc.identifier.scopusauthoridKwong, YL=7102818954en_US
dc.identifier.scopusauthoridKim, WS=34975082200en_US
dc.identifier.scopusauthoridMaeda, Y=54890029900en_US
dc.identifier.scopusauthoridHashimoto, C=7006409531en_US
dc.identifier.scopusauthoridSuh, C=7102970953en_US
dc.identifier.scopusauthoridIzutsu, K=7102942138en_US
dc.identifier.scopusauthoridIshida, F=35399907400en_US
dc.identifier.scopusauthoridIsobe, Y=35481009100en_US
dc.identifier.scopusauthoridSueoka, E=7003546233en_US
dc.identifier.scopusauthoridSuzumiya, J=7005666128en_US
dc.identifier.scopusauthoridKodama, T=7403299362en_US
dc.identifier.scopusauthoridKimura, H=7404270074en_US
dc.identifier.scopusauthoridHyo, R=6506815388en_US
dc.identifier.scopusauthoridNakamura, S=35323670300en_US
dc.identifier.scopusauthoridOshimi, K=7006673135en_US
dc.identifier.scopusauthoridSuzuki, R=35381312500en_US
dc.identifier.citeulike9913592-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats